Navigation Links
Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Date:10/14/2009

RARITAN, N.J., Oct. 14 /PRNewswire/ -- Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is the first HIV diagnostic assay approved for an integrated system in the United States, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples.

"By providing a fast, cost-effective and reliable method for testing HIV, the VITROS® Anti-HIV 1+2 Assay will help enhance the clinical laboratory's ability to adhere to the Centers for Disease Control and Prevention (CDC) HIV screening guidelines, while at the same time increasing the lab's productivity and efficiency," said Mike Samoszuk, M.D., Chief Medical Officer, Ortho Clinical Diagnostics. "This approval underscores Ortho Clinical Diagnostics' continuing commitment to providing clinical laboratories with tests that help detect diseases earlier for better patient outcomes."

The CDC recommends routine screening for people between the ages of 13 and 64 during annual check-ups, pregnant women either before or during pregnancy, and newborns. Currently, more than 230,000 people living with HIV in the U.S. are unaware they have the disease, increasing the need for routine screening.(1) HIV screening plays an invaluable role in early disease detection, prevention and treatment.

The VITROS® Anti-HIV 1+2 Assay is an in vitro diagnostic immunoassay for the qualitative detection of HIV 1+2 in human serum and plasma. It provides physicians with a reliable and quick test for HIV, a virus that causes acquired immunodeficiency syndrome (AIDS) and can lead to death. It may also be used to screen for HIV in pregnant women
'/>"/>

SOURCE Ortho-Clinical Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling $10.7 Million of Annual Net Revenue
2. Wound Management Technologies Acquires Resorbable Orthopedics
3. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
4. Orthopaedic Injury: High Risk to Pregnant Women
5. Children and Orthopaedic Surgical Emergencies
6. American Academy Of Orthopaedic Surgeons 2009 Annual Meeting Highlights and Hot Topics
7. New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
10. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
11. First Human Implant of New Archus Orthopedics Facet Replacement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... recommending that elderly men should not be routinely screened ... to a new study led by researchers at Henry ... online in JAMA Internal Medicine , focused on ... test for prostate cancer., "We found that the effect ... elderly men in particular has been minimal at best," ...
(Date:9/18/2014)... 2014 With the swift industrial development ... such as smart phones, tablets and PDAs, a complete ... mobile devices are viewed these days. From only being ... becoming a mode for creating and delivering content while ... way. , The complete makeover of this ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A sold-out ... community advocates, and volunteers supported United Way of ... Chefs and Fine Wines” event Monday, Sept. 15. Proceeds ... health initiatives in Westchester and Putnam, such as providing ... steering teens away from risky behaviors like drug and ...
Breaking Medicine News(10 mins):Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3
... people who have optic nerve damage might be at ... the study researchers involved 25 people with visual impairment. ... days, and their results were compared with those of ... that those with optic nerve disease were 20-times more ...
... inflammation of the liver and can cause complications such ... the hepatitis B vaccine is recommended for infants. Previous ... against infection for up to 10 years. However, a ... 10 years. ,Researchers followed eight-hundred-and-forty-one Alaska natives vaccinated ...
... of the expectant mother. Now a new study suggests ... of preeclampsia in the pregnant women. ,The ... with periodontitis with atherosclerosis to preeclampsia. Such an oral ... abuse like smoking, etc. The basic reason for setting ...
... and vitamin B12 are safe and effective in reducing the ... a stroke . According to researchers stroke patients have a ... healthy peers due to higher levels of plasma homocysteine in ... of hip fracture. ,The study was initiated to ...
... in Japan, even after the country has banned the shots of ... of the must-have vaccines to be given to children before they ... journal Lancet in 1998 had published a paper relating the MMR ... there had been considerable fall in vaccinating children with MMR (Measles, ...
... benefits of alcohol consumption and cardiovascular disease researchers studied ... // moderate levels of alcohol (one to seven drinks ... eight drinks per week), and did not consume any ... first to focus on the association between alcohol intake ...
Cached Medicine News:
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: